Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now?
Open accessThe DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index; 74 of the 94 sources its claims cite were checked for support.
Abstract
Introduction: Although antimicrobials have traditionally been used to treat infections and improve health outcomes, resistance to commonly used antimicrobials has posed a major challenge. An estimated 700,000 deaths occur globally every year as a result of infections caused by antimicrobial-resistant pathogens. Antimicrobial resistance (AMR) also contributes directly to the decline in the global economy. In 2019, sub-Saharan Africa (SSA) had the highest mortality rate (23.5 deaths per 100,000) attributable to AMR compared to other regions. Methods: We searched PubMed for articles relevant to AMR in pathogens in the WHO-GLASS list and in other infections of local importance in SSA. In this review, we focused on AMR rates and surveillance of AMR for these priority pathogens and some of the most encountered pathogens of public health significance. In addition, we reviewed the implementation of national action plans to mitigate against AMR in countries in SSA. Results and Discussion: The SSA region is disproportionately affected by AMR, in part owing to the prevailing high levels of poverty, which result in a high burden of infectious diseases, poor regulation of antimicrobial use, and a lack of alternatives to ineffective antimicrobials. The global action plan as a strategy for prevention and combating AMR has been adopted by most countries, but fewer countries are able to fully implement country-specific action plans, and several challenges exist in many settings. Conclusion: A concerted One Health approach will be required to ramp up implementation of action plans in the region. In addition to AMR surveillance, effective implementation of infection prevention and control, water, sanitation, and hygiene, and antimicrobial stewardship programs will be key cost-effective strategies in helping to tackle AMR.
Overview
CoChat Summary
TL;DR
This review summarizes antimicrobial resistance rates among WHO-GLASS and locally important pathogens in sub-Saharan Africa and assesses national action plan implementation. It reports that SSA has the highest AMR-attributable mortality and that NAP implementation remains limited by funding, surveillance, and multisectoral coordination gaps.
Key findings
- In 2019, SSA had the highest AMR-attributable mortality rate (23.5 deaths per 100,000), with Western SSA highest at 27.3 deaths per 100,000; globally, 4.95 million deaths were associated with AMR and 1.27 million were attributable to AMR.
- Resistance was widespread among reviewed pathogens: diarrheagenic E. coli prevalence ranged from 14.7% to 82%; multidrug-resistant S. Typhi subclade 4.3.1 prevalence ranged from 60.4% to 97%; MRSA prevalence ranged from 1.25% to 53.4%; carbapenem-resistant P. aeruginosa prevalence ranged from 6% to 34.8%; and East Africa had the highest A. baumannii carbapenem resistance prevalence at 23%.
- NAP implementation was limited: 11 (25%) of 44 SSA countries had NAPs on AMR; 32% performed routine AMR surveillance on clinical pathogens and 2% on veterinary pathogens; 59% had a dedicated National Reference Laboratory; by February 2022, 15 SSA countries had fully developed NAPs. Thematic performance was 38±12% for awareness creation and training, 18±13% for surveillance, 33±13% for infection prevention and control, 28±23% for optimal antimicrobial use, and 59±12% for multisector and One Health collaboration.
- Burden estimates included 141,918 cholera infections per year in SSA; approximately 1.5 million typhoid cases and 19,900 deaths annually in SSA, accounting for about 17% of global typhoid deaths; 421,600 invasive non-typhoidal Salmonella cases and 66,520 deaths in SSA; and 31% of neonatal sepsis mortalities (690,000) plausibly attributed to antimicrobial-resistant infections.
Methods
- Narrative review of English original articles and reviews retrieved from PubMed and Google Scholar, covering the WHO-Africa region divided into Western, Eastern, Central, and Southern SSA; search terms included antimicrobial resistance, multi-drug resistance, sub-Saharan Africa, surveillance, global action plan, national action plan, and One Health approach; articles published between 2000 and 2022 were considered.
- Pathogens were selected as WHO-GLASS priority pathogens plus Vibrio cholerae; inclusion criteria covered articles on selected pathogens from SSA countries, articles reporting antibiotic resistance rates and genes, and both monomicrobial and polymicrobial studies; exclusions were non-WHO-GLASS pathogens, articles from beyond SSA, conference abstracts, intervention trials, and duplicates.
- The review presents resistance rates from cited studies in tables and discusses NAP implementation; it does not report a pooled meta-analysis.
Limitations
- The paper states that precise burden estimates for resistant K. pneumoniae in SSA are lacking and that available data are generated in referral/research/university hospitals, which do not represent the broad range of healthcare settings; it also states that few A. baumannii reports come from low-income countries, making prevalence estimates difficult.
- The paper states that the paucity of data in SSA on AMR prevalence and antimicrobial use is a major impediment, and it lists NAP implementation challenges including inadequate funding, poor coordination, inadequate surveillance data, poor infrastructure and health systems, staffing shortages, and lack of monitoring and quality assurance systems.
- Evident from the text: as a narrative review using PubMed/Google Scholar and heterogeneous published studies, resistance rates are not pooled or systematically appraised, and many estimates come from single-center or referral-hospital studies that may not be generalizable.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
50 Valid · 5 Not valid · 14 Not checked · 32 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In 2019, sub-Saharan Africa (SSA) had the highest mortality rate (23.5 deaths per 100,000) attributable to AMR compared to other regions.”
- Also stated in: § Impact of Antimicrobial Resistance · plain
“Compared to other Global Burden of Disease study regions, sub-Saharan Africa (SSA) and South Asia had the highest mortalities (23.5 deaths per 100,000 and 21.5 deaths per 100,000, respectively) attributable to AMR.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Abstract
What the sources say
- Partly supportedcites [8] Murray, 2022, Lancet sourceExperimental — accuracy not yet measured
The Results report that sub-Saharan Africa had the highest all-age death rate attributable to AMR in 2019. However, they give 27.3 deaths per 100,000 for western sub-Saharan Africa, the highest of the 21 regions; our copy does not substantiate the claimed 23.5 deaths per 100,000 for sub-Saharan Africa as a whole. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Impact of Antimicrobial Resistance · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“Indeed, the rapid emergence of antimicrobial-resistant pathogens is often accelerated by the inappropriate use and overuse of antimicrobial agents, especially antibiotics, in humans, animals, and agriculture/the environment.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Role of Antimicrobial Use in Increasing Rates of AMR
What the sources say
- Supportedcites [18] Sartelli, 2020, Antibiotics source
Section 2, “Antimicrobial Resistance: A Global Challenge,” says antibiotic use, misuse and abuse in human, animal and environmental sectors drive AMR, and that misuse selects resistant microorganisms. Section 3, “Antimicrobial Resistance in LMICs,” also identifies antibiotic use in agriculture as a challenge. (LLM, conf=0.94)
- Supportedcites [19] Van, 2020, J Glob Antimicrob Resist source
The Introduction identifies repeated antibiotic use in food animals as a significant contributor to antimicrobial resistance and acknowledges the contribution of misuse in humans. Section 4 says widespread antibiotic use in animals accelerates the emergence of resistance and describes the environment as a reservoir and route of spread, including antibiotic use in aquaculture. (LLM, conf=0.90)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In neonatal sepsis, 31% of mortalities (690,000) reported were plausibly attributed to antimicrobial-resistant infections.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Impact of Antimicrobial Resistance
What the sources say
- Supportedcites [11] Li, 2020, Arch Dis Child source
The Introduction reports a previous estimate that 214,000 of 690,000 annual neonatal deaths associated with sepsis (31%) were potentially attributable to antimicrobial resistance. The paper presents this as an estimate from Laxminarayan et al., not a finding of the NeoAMR study. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The study found that the consumption rate increased from 9.8 (9.2-10.5)daily defined doses (DDD) to 14.3 (13.2-15.6)DDD per 1000 population per day.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Role of Antimicrobial Use in Increasing Rates of AMR
What the sources say
- Supportedcites [26] Browne, 2021, Lancet Planetary Health source
The Results report that global antibiotic consumption rose from 9.8 (95% uncertainty interval 9.2–10.5) to 14.3 (13.2–15.6) defined daily doses per 1000 people per day between 2000 and 2018. These are the figures and period attributed to the study. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A study published in 2021 reported that there was a 46% increase in the global consumption of antimicrobials between 2000 and 2018.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Role of Antimicrobial Use in Increasing Rates of AMR
What the sources say
- Partly supportedcites [26] Browne, 2021, Lancet Planetary Health sourceExperimental — accuracy not yet measured
The Introduction (Added value of this study) reports a 46% increase in global antibiotic consumption since 2000, and the Results give the 2000 and 2018 consumption rates. The study measures antibiotics, not antimicrobials as a whole, so the claim broadens its scope. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
38 more claims · 18 with their cited sources checked
Create a free account to see all 101 claims and to verify the 4 references still open.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 42
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such sparsity is mainly due to insufficient laboratory infrastructure and capacity, scarce or absent microbiological facilities, weak health systems and governance and information systems, and scarce resources.60, 72, 73”
From Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 (2024) · cites this paper as [73]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Carbapenem-Resistant Acinetobacter baumannii
“Out of the 29 countries, only 16 countries reported the detection of A. baumannii within their territories at least once in the last 21 years.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Carbapenem-Resistant Acinetobacter baumannii
“Accordingly, 11 out of the 29 have no A. baumannii reports at all in the three searched databases.”
Citations
Cites
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316 · cited 2×
“aeruginosa accounting for 38,100 deaths globally.(151) The prevalence of carbapenem-resistant P.”
BackgroundTacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30753-3 · Cited by 6,142 · cited 2×
“aeruginosa as one of the three critical global priority pathogens that require development of new antibiotics.(144) It is estimated that in 2019, antimicrobialresistant P.”
BackgroundAcinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316 · cited 1×
“Acinetobacter baumannii is often implicated in bloodstream, urinary tract, pneumonia, skin and soft tissue infections, and meningitis.(138,139) Owing to its AMR,(140) A.”
BackgroundAntibiotic resistance in the environment
Larsson, D. G. J., & Flach, C.-F. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00649-x · Cited by 3,164
Cassini, A., Högberg, L. D., Plachouras, D., Quattrocchi, A., Hoxha, A., Simonsen, G. S., Colomb-Cotinat, M., Kretzschmar, M. E., Devleesschauwer, B., Cecchini, M., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30605-4 · Cited by 2,945 · cited 1×
“conducted in the European Union, published in 2019, estimates an annual number of disability-adjusted life-years (DALYs) at 148,727 (131,757–166,361) per 1,000,000 population, infections at 112,782 (103,186–122,006), and attributable deaths at 6810 (6096–7559).(156) While surveillance systems are in place in developed…”
BackgroundAntimicrobial Resistance: Implications and Costs
Dadgostar, P. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s234610 · Cited by 2,024 · cited 1×
“Infections caused by antimicrobial-resistant pathogens are reported to result in approximately 700,000 deaths globally every year.(3)”
BackgroundManyi-Loh, C., Mamphweli, S., Meyer, E., & Okoh, A. (2018) · Molecules · doi:10.3390/molecules23040795 · Cited by 1,808 · cited 19×
“Some of the challenges that hinder the implementation of NAPs are: 1) a lack of political commitment, 2) inadequate funding, 3) poor coordination and collaboration between the different sectors, 4) inadequate surveillance Infection and Drug Resistance 2022:15 https://doi.org/10.2147/IDR.S342753 DovePress 3601 Powered…”
BackgroundInfluentialTroeger, C., Blacker, B. F., Khalil, I. A., Rao, P. C., Cao, S., Zimsen, S. R., Albertson, S. B., Stanaway, J. D., Deshpande, A., Abebe, Z., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30362-1 · Cited by 1,476 · cited 1×
“According to the 2016 Global Burden of Disease (GBD) report, cumulatively these two pathotypes result in 63,523 deaths among all ages annually, throughout the world.(36) Other important E.”
BackgroundThe threat of antimicrobial resistance in developing countries: causes and control strategies
Ayukekbong, J. A., Ntemgwa, M., & Atabe, A. N. (2017) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-017-0208-x · Cited by 1,315 · cited 17×
“Some of the challenges that hinder the implementation of NAPs are: 1) a lack of political commitment, 2) inadequate funding, 3) poor coordination and collaboration between the different sectors, 4) inadequate surveillance Infection and Drug Resistance 2022:15 https://doi.org/10.2147/IDR.S342753 DovePress 3601 Powered…”
BackgroundInfluentialHealth systems financing and the path to universal coverage
Evans, D. B., & Etienne, C. (2010) · Bulletin of the World Health Organization · doi:10.2471/blt.10.078741 · Cited by 1,279
Antimicrobial Resistance: a One Health Perspective
McEwen, S. A., & Collignon, P. J. (2018) · Microbiology Spectrum · doi:10.1128/microbiolspec.arba-0009-2017 · Cited by 1,199
Global trends in antimicrobial resistance in animals in low- and middle-income countries
Van Boeckel, T. P., Pires, J., Silvester, R., Zhao, C., Song, J., Criscuolo, N. G., Gilbert, M., Bonhoeffer, S., & Laxminarayan, R. (2019) · Science · doi:10.1126/science.aaw1944 · Cited by 1,160
Population genomics of Klebsiella pneumoniae
Wyres, K. L., Lam, M. M. C., & Holt, K. E. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0315-1 · Cited by 1,160
The World Health Organization Global Action Plan for antimicrobial resistance
Mendelson, M., & Matsoso, M. P. (2015) · South African Medical Journal · doi:10.7196/samj.9644 · Cited by 1,155 · cited 19×
“Some of the challenges that hinder the implementation of NAPs are: 1) a lack of political commitment, 2) inadequate funding, 3) poor coordination and collaboration between the different sectors, 4) inadequate surveillance Infection and Drug Resistance 2022:15 https://doi.org/10.2147/IDR.S342753 DovePress 3601 Powered…”
BackgroundInfluentialAntimicrobial resistance: A global emerging threat to public health systems
Ferri, M., Ranucci, E., Romagnoli, P., & Giaccone, V. (2017) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2015.1077192 · Cited by 1,049 · cited 1×
“0 million, while in the USA the cost is approximately $55 billion.(15) According to projections by RAND Europe, the economic loss due to AMR would be the highest in the SSA region if no intervention were implemented.”
BackgroundThe negative impact of antibiotic resistance
Friedman, N. D., Temkin, E., & Carmeli, Y. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.12.002 · Cited by 870 · cited 1×
“The clinical effects of AMR include severe infections, increased morbidity, treatment failure, and mortality.(7) In 2019, an estimated 4.”
BackgroundGlobal antibiotic consumption and usage in humans, 2000–18: a spatial modelling study
Browne, A. J., Chipeta, M. G., Haines-Woodhouse, G., Kumaran, E. P. A., Hamadani, B. H. K., Zaraa, S., Henry, N. J., Deshpande, A., Reiner, R. C., Day, N. P. J., et al. (2021) · The Lancet Planetary Health · doi:10.1016/s2542-5196(21)00280-1 · Cited by 865 · cited 1×
“A study published in 2021 reported that there was a 46% increase in the global consumption of antimicrobials between 2000 and 2018.(26) The study found that the consumption rate increased from 9.”
BackgroundAcinetobacter baumannii: An emerging opportunistic pathogen
Howard, A., O’Donoghue, M., Feeney, A., & Sleator, R. D. (2012) · Virulence · doi:10.4161/viru.19700 · Cited by 837
Stanaway, J. D., Reiner, R. C., Blacker, B. F., Goldberg, E. M., Khalil, I. A., Troeger, C. E., Andrews, J. R., Bhutta, Z. A., Crump, J. A., Im, J., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30685-6 · Cited by 835 · cited 2×
“5 million cases are reported annually and 19,900 deaths, accounting for approximately 17% of global deaths.(65) In the 1980s in most SSA”
BackgroundNosocomial infections: Epidemiology, prevention, control and surveillance
Khan, H. A., Baig, F. K., & Mehboob, R. (2017) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/j.apjtb.2017.01.019 · Cited by 824 · cited 1×
“pneumoniae are poor hand hygiene among healthcare workers, contaminated medical equipment, and poor waste management practices in hospitals.(123,124) These drivers are associated with inadequate supply of equipment, poor infrastructure relating to infection control, and understaffed healthcare settings, which result i…”
BackgroundCollignon, P., Beggs, J. J., Walsh, T. R., Gandra, S., & Laxminarayan, R. (2018) · The Lancet Planetary Health · doi:10.1016/s2542-5196(18)30186-4 · Cited by 750 · cited 1×
“It has been shown that the reduction of inappropriate antimicrobial use directly contributes to the decrease in the development of AMR; however, this alone would not be adequate to deal with the global AMR challenge.(32) Consequently, there is a need to control the high rate of emergence and spread of antimicrobial-re…”
BackgroundEpidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria
Nordmann, P., & Poirel, L. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz824 · Cited by 721 · cited 1×
“baumannii.(143) Acinetobacter baumannii has a high propensity for intrinsic resistance to different antibiotics and the ability to acquire different antibiotic resistance genes.”
BackgroundIdentifying Key Challenges Facing Healthcare Systems In Africa And Potential Solutions
Oleribe, O. E., Momoh, J., Uzochukwu, B. S., Mbofana, F., Adebiyi, A., Barbera, T., Williams, R., & Taylor Robinson, S. D. (2019) · International Journal of General Medicine · doi:10.2147/ijgm.s223882 · Cited by 685 · cited 6×
“This review has highlighted the AMR rates in different WHO-GLASS and locally important enteric pathogenic bacteria, and the successes and challenges in the implementation of NAPs in sub-Saharan Africa.”
BackgroundInfluentialAcinetobacter baumannii Antibiotic Resistance Mechanisms
Kyriakidis, I., Vasileiou, E., Pana, Z. D., & Tragiannidis, A. (2021) · Pathogens · doi:10.3390/pathogens10030373 · Cited by 678
Global Contributors to Antibiotic Resistance
Chokshi, A., Sifri, Z., Cennimo, D., & Horng, H. (2019) · Journal of Global Infectious Diseases · doi:10.4103/jgid.jgid_110_18 · Cited by 647
Stanaway, J. D., Parisi, A., Sarkar, K., Blacker, B. F., Reiner, R. C., Hay, S. I., Nixon, M. R., Dolecek, C., James, S. L., Mokdad, A. H., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30418-9 · Cited by 645
Antibiotic Resistance: One Health One World Outlook
Aslam, B., Khurshid, M., Arshad, M. I., Muzammil, S., Rasool, M., Yasmeen, N., Shah, T., Chaudhry, T. H., Rasool, M. H., Shahid, A., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.771510 · Cited by 609 · cited 1×
“One Health Approach to Tackle AMR The One Health approach is an important concept that recognizes the inseparable links between human, animal, and environmental health.(188) Although AMR surveillance studies have mainly focused on humans and animals, the environment is a critical aspect in the control of AMR.”
BackgroundShrivastava, S., Shrivastava, P., & Ramasamy, J. (2018) · Journal of Medical Society · doi:10.4103/jms.jms_25_17 · Cited by 583 · cited 1×
“pneumoniae as public health priorities.(120) In SSA, precise burden estimates for resistant K.”
BackgroundKingsley, R. A., Msefula, C. L., Thomson, N. R., Kariuki, S., Holt, K. E., Gordon, M. A., Harris, D., Clarke, L., Whitehead, S., Sangal, V., et al. (2009) · Genome Research · doi:10.1101/gr.091017.109 · Cited by 540
Self-citationWong, V. K., Baker, S., Pickard, D. J., Parkhill, J., Page, A. J., Feasey, N. A., Kingsley, R. A., Thomson, N. R., Keane, J. A., Weill, F.-X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3281 · Cited by 471
Self-citationSalmonella infections in immunocompromised adults
Gordon, M. A. (2008) · Journal of Infection · doi:10.1016/j.jinf.2008.03.012 · Cited by 453
Antibiotic use in food animals worldwide, with a focus on Africa: Pluses and minuses
Van, T. T. H., Yidana, Z., Smooker, P. M., & Coloe, P. J. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2019.07.031 · Cited by 451 · cited 2×
“In food-producing animals, antimicrobials are mainly used for the prevention and treatment of disease.(19,29,30) Although the use of antimicrobials is important in ensuring the health of the animals, prolonged use for non-therapeutic purposes (eg prophylaxis, growth promotion), and often at sub-therapeutic levels, con…”
BackgroundRole of the Environment in the Transmission of Antimicrobial Resistance to Humans: A Review
Huijbers, P. M. C., Blaak, H., de Jong, M. C. M., Graat, E. A. M., Vandenbroucke-Grauls, C. M. J. E., & de Roda Husman, A. M. (2015) · Environmental Science & Technology · doi:10.1021/acs.est.5b02566 · Cited by 425 · cited 17×
“Some of the challenges that hinder the implementation of NAPs are: 1) a lack of political commitment, 2) inadequate funding, 3) poor coordination and collaboration between the different sectors, 4) inadequate surveillance Infection and Drug Resistance 2022:15 https://doi.org/10.2147/IDR.S342753 DovePress 3601 Powered…”
BackgroundInfluentialDeng, M.-T., Zhu, F., Yang, Y.-Z., Yang, F.-X., Hao, J.-P., Chen, S.-R., & Hou, Z.-C. (2019) · BMC Genomics · doi:10.1186/s12864-018-5379-1 · Cited by 383
Self-medication and antibiotic resistance: Crisis, current challenges, and prevention
Rather, I. A., Kim, B.-C., Bajpai, V. K., & Park, Y.-H. (2017) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2017.01.004 · Cited by 379
Global geographic trends in antimicrobial resistance: the role of international travel
Frost, I., Van Boeckel, T. P., Pires, J., Craig, J., & Laxminarayan, R. (2019) · Journal of Travel Medicine · doi:10.1093/jtm/taz036 · Cited by 338 · cited 1×
“However, AMR prevalence varies considerably geographically in different continents, regions, and countries.(35) In SSA, different pathogens were found to have varying rates of resistance to different antimicrobial agents and these may be different from region to region.”
BackgroundOkomo, U., Akpalu, E. N. K., Le Doare, K., Roca, A., Cousens, S., Jarde, A., Sharland, M., Kampmann, B., & Lawn, J. E. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30414-1 · Cited by 321 · cited 1×
“aureus.(117,118) It is an opportunistic pathogen which causes infections on otherwise sterile sites, for example septicemia, bacteremia, and infections of the respiratory tract, urinary tract, and central nervous system.”
BackgroundAcinetobacter baumannii Resistance: A Real Challenge for Clinicians
Vázquez-López, R., Solano-Gálvez, S. G., Juárez Vignon-Whaley, J. J., Abello Vaamonde, J. A., Padró Alonzo, L. A., Rivera Reséndiz, A., Muleiro Álvarez, M., Vega López, E. N., Franyuti-Kelly, G., Álvarez-Hernández, D. A., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9040205 · Cited by 296
Raman, G., Avendano, E. E., Chan, J., Merchant, S., & Puzniak, L. (2018) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-018-0370-9 · Cited by 269 · cited 1×
“aeruginosa infections include prior hospitalization, ICU stay, and previous use of antibiotics.(174) Pseudomonas aeruginosa has an intrinsic ability to develop resistance to frequently used antibiotics, which often leads to treatment failure.”
BackgroundUche, I. V., MacLennan, C. A., & Saul, A. (2017) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0005118 · Cited by 232
Mobile Carbapenemase Genes in Pseudomonas aeruginosa
Yoon, E.-J., & Jeong, S. H. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.614058 · Cited by 221
Kariuki, S., Revathi, G., Kariuki, N., Kiiru, J., Mwituria, J., Muyodi, J., Githinji, J. W., Kagendo, D., Munyalo, A., & Hart, C. A. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46375-0 · Cited by 216
Self-citationCommunity-acquired Acinetobacter baumannii: clinical characteristics, epidemiology and pathogenesis
Dexter, C., Murray, G. L., Paulsen, I. T., & Peleg, A. Y. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1025055 · Cited by 201
The utility of diagnostic tests for enteric fever in endemic locations
Parry, C. M., Wijedoru, L., Arjyal, A., & Baker, S. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.47 · Cited by 198 · cited 1×
“The economic effects of AMR comprise increased length of hospitalization, higher healthcare costs,(7,12) and decreased labor supply and labor efficiency.(13) The global economic cost associated with AMR is estimated to be US$ 100 trillion by 2050 if the current trend persists.”
BackgroundLessler, J., Moore, S. M., Luquero, F. J., McKay, H. S., Grais, R., Henkens, M., Mengel, M., Dunoyer, J., M'bangombe, M., Lee, E. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33050-7 · Cited by 192
de Mesquita Souza Saraiva, M., Lim, K., do Monte, D. F. M., Givisiez, P. E. N., Alves, L. B. R., de Freitas Neto, O. C., Kariuki, S., Júnior, A. B., de Oliveira, C. J. B., & Gebreyes, W. A. (2022) · Brazilian Journal of Microbiology · doi:10.1007/s42770-021-00635-8 · Cited by 184
Self-citationNew epidemiology of Staphylococcus aureus infection in Africa
Schaumburg, F., Alabi, A. S., Peters, G., & Becker, K. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12690 · Cited by 174
Diagnostics for invasive Salmonella infections: Current challenges and future directions
Andrews, J. R., & Ryan, E. T. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.02.030 · Cited by 174 · cited 1×
“The development of novel diagnostic tools is challenging owing to the diversity of NTS serotypes, but the use of locally targeted lipopolysaccharide antigen is likely to be useful.(79,111) Third generation cephalosporins (ceftriaxone) and fluoroquinolones (ciprofloxacin) are the mainstay of iNTS treatment.”
BackgroundAn extended genotyping framework for Salmonella enterica serovar Typhi, the cause of human typhoid
Wong, V. K., Baker, S., Connor, T. R., Pickard, D., Page, A. J., Dave, J., Murphy, N., Holliman, R., Sefton, A., Millar, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms12827 · Cited by 171 · cited 1×
“Typhi populations were classified into 85 haplotypes (haploid genotypes), but currently, they are categorized into four clusters, 16 clades, and 49 subclades.(74) Subclade 4.”
BackgroundSelf-citationRapid Emergence of Multidrug Resistant, H58-Lineage Salmonella Typhi in Blantyre, Malawi
Feasey, N. A., Gaskell, K., Wong, V., Msefula, C., Selemani, G., Kumwenda, S., Allain, T. J., Mallewa, J., Kennedy, N., Bennett, A., et al. (2015) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0003748 · Cited by 167
Acinetobacter baumannii: An Emerging Multidrug-Resistant Pathogen in Critical Care
Montefour, K., Frieden, J., Hurst, S., Helmich, C., Headley, D., Martin, M., & Boyle, D. A. (2008) · Critical Care Nurse · doi:10.4037/ccn2008.28.1.15 · Cited by 165
Ayobami, O., Willrich, N., Harder, T., Okeke, I. N., Eckmanns, T., & Markwart, R. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1698273 · Cited by 163 · cited 2×
“baumannii), is the most clinically relevant.(132,133) Acinetobacter baumannii accounts for the majority (approximately 90%) of clinical infections, followed by A.”
BackgroundKariuki, S., Revathi, G., Kiiru, J., Mengo, D. M., Mwituria, J., Muyodi, J., Munyalo, A., Teo, Y. Y., Holt, K. E., Kingsley, R. A., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01983-09 · Cited by 158
Self-citationMapping Global Prevalence of Acinetobacter baumannii and Recent Vaccine Development to Tackle It
Ma, C., & McClean, S. (2021) · Vaccines · doi:10.3390/vaccines9060570 · Cited by 157
Invasive Nontyphoidal Salmonella Disease in Africa
Gilchrist, J. J., & MacLennan, C. A. (2019) · EcoSal Plus · doi:10.1128/ecosalplus.esp-0007-2018 · Cited by 154 · cited 1×
“In addition, most NTS infections present as invasive disease, especially among children less than 5 years of age and those with underlying immunosuppressive conditions.(95) Of all the NTS serotypes, S.”
BackgroundPierce, J., Apisarnthanarak, A., Schellack, N., Cornistein, W., Maani, A. A., Adnan, S., & Stevens, M. P. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.05.126 · Cited by 154 · cited 1×
“Lack of personnel has also been identified as a barrier to antimicrobial stewardship programs.(202) The inadequacy of staff working on AMR limits the implementation of NAPs at the country level.”
BackgroundStepwise evolution of Salmonella Typhimurium ST313 causing bloodstream infection in Africa
Pulford, C. V., Perez-Sepulveda, B. M., Canals, R., Bevington, J. A., Bengtsson, R. J., Wenner, N., Rodwell, E. V., Kumwenda, B., Zhu, X., Bennett, R. J., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00836-1 · Cited by 151
Sartelli, M., C. Hardcastle, T., Catena, F., Chichom-Mefire, A., Coccolini, F., Dhingra, S., Haque, M., Hodonou, A., Iskandar, K., Labricciosa, F. M., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9080497 · Cited by 149
Bachou, H., Tylleskär, T., Kaddu-Mulindwa, D. H., & Tumwine, J. K. (2006) · BMC Infectious Diseases · doi:10.1186/1471-2334-6-160 · Cited by 137
Ateshim, Y., Bereket, B., Major, F., Emun, Y., Woldai, B., Pasha, I., Habte, E., & Russom, M. (2019) · BMC Public Health · doi:10.1186/s12889-019-7020-x · Cited by 127
Antimicrobial resistance preparedness in sub-Saharan African countries
Elton, L., Thomason, M. J., Tembo, J., Velavan, T. P., Pallerla, S. R., Arruda, L. B., Vairo, F., Montaldo, C., Ntoumi, F., Abdel Hamid, M. M., et al. (2020) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-020-00800-y · Cited by 125 · cited 2×
“A high number of East African countries was found to be undertaking AMR surveillance in human and animal pathogens.(193,194) Southern African countries were found to have the highest rate of developing antimicrobial stewardship guidelines and antimicrobial legislation.”
BackgroundAli, S., Birhane, M., Bekele, S., Kibru, G., Teshager, L., Yilma, Y., Ahmed, Y., Fentahun, N., Assefa, H., Gashaw, M., et al. (2018) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-017-0298-5 · Cited by 122 · cited 1×
“In SSA, high-risk populations are newborns and patients admitted to intensive care units (ICUs), especially those with underlying comorbidities.(121,122) The main driving factors for resistant K.”
BackgroundMarin, M. A., Thompson, C. C., Freitas, F. S., Fonseca, E. L., Aboderin, A. O., Zailani, S. B., Quartey, N. K. E., Okeke, I. N., & Vicente, A. C. P. (2013) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0002049 · Cited by 121 · cited 2×
“cholerae isolates have become resistant to penicillins, aminoglycosides and sulfonamides, quinolones, tetracycline, macrolides, and phenicols, and more recently several studies have reported strains showing reduced susceptibility to fluoroquinolones and third generation cephalosporins.(54,57,58,60) This resistance has…”
BackgroundMethodThe phylogeography and incidence of multi-drug resistant typhoid fever in sub-Saharan Africa
Park, S. E., Pham, D. T., Boinett, C., Wong, V. K., Pak, G. D., Panzner, U., Espinoza, L. M. C., von Kalckreuth, V., Im, J., Schütt-Gerowitt, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07370-z · Cited by 120
Fadare, J. O., Ogunleye, O. O., Iliyasu, G., Adeoti, A. O., Schellack, N., Engler, D., Massele, A. Y., & Godman, B. (2018) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2018.11.025 · Cited by 119
Yeika, E. V., Ingelbeen, B., Kemah, B., Wirsiy, F. S., Fomengia, J. N., & van der Sande, M. A. B. (2021) · Tropical Medicine & International Health · doi:10.1111/tmi.13600 · Cited by 116
Munkholm, L., & Rubin, O. (2020) · Globalization and Health · doi:10.1186/s12992-020-00639-3 · Cited by 115 · cited 4×
“Globally, two-thirds of the 194 WHO member states are reported to have developed NAPs.192 The overall performance of SSA countries in the implementation of NAPs has been reported to be inadequate.”
BackgroundMethodInfluentialPolymyxins and Their Potential Next Generation as Therapeutic Antibiotics
Vaara, M. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01689 · Cited by 113 · cited 1×
“baumannii, its widespread antibiotic resistance, and most recently, the unforeseen emergence and spread of clinical isolates resistant to colistin, the last resort in current antimicrobial therapy, all necessitate its inclusion in national surveillance systems and national action plans.(141,142) According to the WHO-G…”
BackgroundA Perspective on Invasive Salmonella Disease in Africa
Crump, J. A., & Heyderman, R. S. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ709 · Cited by 112
Egyir, B., Guardabassi, L., Sørum, M., Nielsen, S. S., Kolekang, A., Frimpong, E., Addo, K. K., Newman, M. J., & Larsen, A. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089716 · Cited by 108
Klebsiella pneumoniae ST307 with bla OXA-181, South Africa, 2014–2016
Lowe, M., Kock, M. M., Coetzee, J., Hoosien, E., Peirano, G., Strydom, K., Ehlers, M. M., Mbelle, N. M., Shashkina, E., Haslam, D. B., et al. (2019) · Emerging infectious diseases · doi:10.3201/eid2504.181482 · Cited by 108
Climatic Drivers of Diarrheagenic Escherichia coli Incidence: A Systematic Review and Meta-analysis
Philipsborn, R., Ahmed, S. M., Brosi, B. J., & Levy, K. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiw081 · Cited by 107
Li, G., Bielicki, J. A., Ahmed, A. S. M. N. U., Islam, M. S., Berezin, E. N., Gallacci, C. B., Guinsburg, R., da Silva Figueiredo, C. E., Santarone Vieira, R., Silva, A. R., et al. (2020) · Archives of Disease in Childhood · doi:10.1136/archdischild-2019-316816 · Cited by 106
Incidence of non-typhoidal Salmonella invasive disease: A systematic review and meta-analysis
Marchello, C. S., Fiorino, F., Pettini, E., Crump, J. A., Martín, L., Breghi, G., Canals, R., Gordon, M. A., Hanumunthadu, B., Jacobs, J. A., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.06.029 · Cited by 106 · cited 1×
“cases of person-years of observation (pyo).(94) In most parts of SSA, iNTS presents as non-specific febrile illness, which poses a major challenge in diagnosis as it is difficult to distinguish from other febrile illnesses endemic in these settings, such as malaria.”
BackgroundSelf-citationIsendahl, J., Turlej-Rogacka, A., Manjuba, C., Rodrigues, A., Giske, C. G., & Nauclér, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051981 · Cited by 103
Mshana, S. E., Sindato, C., Matee, M. I., & Mboera, L. E. G. (2021) · Antibiotics · doi:10.3390/antibiotics10080976 · Cited by 102
Feasey, N. A., Masesa, C., Jassi, C., Faragher, E. B., Mallewa, J., Mallewa, M., MacLennan, C. A., Msefula, C., Heyderman, R. S., & Gordon, M. A. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ691 · Cited by 100
Methicillin-resistant Staphylococcus aureus (MRSA) in East Africa: red alert or red herring?
Wangai, F. K., Masika, M. M., Maritim, M. C., & Seaton, R. A. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4245-3 · Cited by 94
A systematic review: the current status of carbapenem resistance in East Africa
Ssekatawa, K., Byarugaba, D. K., Wampande, E., & Ejobi, F. (2018) · BMC Research Notes · doi:10.1186/s13104-018-3738-2 · Cited by 93 · cited 1×
“baumannii had the highest prevalence (23%) of carbapenem resistance compared to other multidrug-resistant bacteria.(148) There are currently no vaccines available against A.”
BackgroundInvasive Salmonella Infections in Areas of High and Low Malaria Transmission Intensity in Tanzania
Biggs, H. M., Lester, R., Nadjm, B., Mtove, G., Todd, J. E., Kinabo, G. D., Philemon, R., Amos, B., Morrissey, A. B., Reyburn, H., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit798 · Cited by 91
Hendriksen, R. S., Leekitcharoenphon, P., Lukjancenko, O., Lukwesa-Musyani, C., Tambatamba, B., Mwaba, J., Kalonda, A., Nakazwe, R., Kwenda, G., Jensen, J. D., et al. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.02026-14 · Cited by 90
Tabu, C., Breiman, R. F., Ochieng, B., Aura, B., Cosmas, L., Audi, A., Olack, B., Bigogo, G., Ongus, J. R., Fields, P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031237 · Cited by 87
Kateete, D. P., Nakanjako, R., Namugenyi, J., Erume, J., Joloba, M. L., & Najjuka, C. F. (2016) · SpringerPlus · doi:10.1186/s40064-016-2986-7 · Cited by 84
Henson, S. P., Boinett, C. J., Ellington, M. J., Kagia, N., Mwarumba, S., Nyongesa, S., Mturi, N., Kariuki, S., Scott, J. A. G., Thomson, N. R., et al. (2017) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2017.07.006 · Cited by 80
Self-citationPark, S. E., Pak, G. D., Aaby, P., Adu-Sarkodie, Y., Ali, M., Aseffa, A., Biggs, H. M., Bjerregaard-Andersen, M., Breiman, R. F., Crump, J. A., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ893 · Cited by 79
Iwu, C. D., & Patrick, S. M. (2021) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2021.106411 · Cited by 78 · cited 11×
“One of the challenges identified in the implementation of NAPs in Mozambique was the poor collaboration between the different sectors.(194) Data on disease epidemiology, AMR, antibiotic consumption, environmental exposure pathways, access to healthcare, morbidity, hospital readmission rates, length of stay in hospital…”
BackgroundResultInfluentialMusoke, D., Namata, C., Lubega, G. B., Niyongabo, F., Gonza, J., Chidziwisano, K., Nalinya, S., Nuwematsiko, R., & Morse, T. (2021) · Environmental Health and Preventive Medicine · doi:10.1186/s12199-021-01023-2 · Cited by 76
Founou, R. C., Founou, L. L., Allam, M., Ismail, A., & Essack, S. Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-42672-2 · Cited by 73
Incidence, pathogens and resistance patterns of nosocomial infections at a rural hospital in Gabon
Scherbaum, M., Kösters, K., Mürbeth, R. E., Ngoa, U. A., Kremsner, P. G., Lell, B., & Alabi, A. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-124 · Cited by 72
Kateete, D. P., Namazzi, S., Okee, M., Okeng, A., Baluku, H., Musisi, N. L., Katabazi, F. A., Joloba, M. L., Ssentongo, R., & Najjuka, F. C. (2011) · BMC Research Notes · doi:10.1186/1756-0500-4-326 · Cited by 72 · cited 1×
“This has been attributed to the presence of several genes; aac(6’)-Ie-aph(2”)-Ia, aph(3’)-IIIa, ant(4’)-Ia, apH3, and aacA-aphD, conferring resistance to aminoglycosides; tetK/M genes against tetracycline; dfrG/dfrA genes against trimethoprim; ermA, ermC, or msrA genes against clindamycin; and gyrA and grlA genes agai…”
BackgroundTyphoid Fever: Tracking the Trend in Nigeria
Akinyemi, K. O., Oyefolu, A. O. B., Mutiu, W. B., Iwalokun, B. A., Ayeni, E. S., Ajose, S. O., & Obaro, S. K. (2018) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.18-0045 · Cited by 72
Baloi, L. D., Baltazar, C. S., Manhique-Coutinho, L. V., Chitio, J. J. E., Inguane, D., & Langa, J. P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181496 · Cited by 71
Gitau, W., Masika, M., Musyoki, M., Museve, B., & Mutwiri, T. (2018) · BMC Research Notes · doi:10.1186/s13104-018-3337-2 · Cited by 71
Ayepola, O. O., Olasupo, N. A., Egwari, L. O., Becker, K., & Schaumburg, F. (2015) · PLOS ONE · doi:10.1371/journal.pone.0137531 · Cited by 68
Kariuki, S., Okoro, C., Kiiru, J., Njoroge, S., Omuse, G., Langridge, G., Kingsley, R. A., Dougan, G., & Revathi, G. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00078-15 · Cited by 68
Self-citationMbelle, N. M., Feldman, C. H., Sekyere, J. O., Maningi, N. E., Modipane, L., & Essack, S. Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-58012-8 · Cited by 68
A one health framework to estimate the cost of antimicrobial resistance
the GAP-ON€ network, Morel, C. M., Alm, R. A., Årdal, C., Bandera, A., Bruno, G. M., Carrara, E., Colombo, G. L., de Kraker, M. E. A., Essack, S. Y., et al. (2020) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-020-00822-6 · Cited by 68 · cited 17×
“Some of the challenges that hinder the implementation of NAPs are: 1) a lack of political commitment, 2) inadequate funding, 3) poor coordination and collaboration between the different sectors, 4) inadequate surveillance Infection and Drug Resistance 2022:15 https://doi.org/10.2147/IDR.S342753 DovePress 3601 Powered…”
BackgroundInfluentialHayat, K., Rosenthal, M., Gillani, A. H., Zhai, P., Aziz, M. M., Ji, W., Chang, J., Hu, H., & Fang, Y. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16091565 · Cited by 67 · cited 1×
“Impact of Antimicrobial Resistance The impact of AMR can be classified as either clinical or economic.(6) The clinical effects of AMR include severe infections, increased morbidity, treatment failure, and mortality.”
BackgroundLunguya, O., Lejon, V., Phoba, M.-F., Bertrand, S., Vanhoof, R., Verhaegen, J., Smith, A. M., Keddy, K. H., Muyembe-Tamfum, J.-J., & Jacobs, J. (2012) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0001921 · Cited by 64 · cited 2×
“Subsequently, S. Typhi isolates with reduced susceptibility to these antimicrobials have now been reported in Kenya,68,69 South Africa,70 and Congo.71 In a study undertaken in Ibadan, Nigeria, 4.0% of febrile patients with bacteremia were found to be positive for S. Typhi, while 1% had invasive non-typhoidal Salmonell…”
BackgroundInfluentialTapia, M. D., Tennant, S. M., Bornstein, K., Onwuchekwa, U., Tamboura, B., Maiga, A., Sylla, M. B., Sissoko, S., Kourouma, N., Toure, A., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ729 · Cited by 61
Varma, J. K., Oppong-Otoo, J., Ondoa, P., Perovic, O., Park, B. J., Laxminarayan, R., Peeling, R. W. W., Schultsz, C., Li, H., Ihekweazu, C. A., et al. (2018) · African Journal of Laboratory Medicine · doi:10.4102/ajlm.v7i2.830 · Cited by 60
Diarrheagenic Escherichia coli Pathotypes From Children Younger Than 5 Years in Kano State, Nigeria
Saka, H. K., Dabo, N. T., Muhammad, B., García-Soto, S., Ugarte-Ruiz, M., & Alvarez, J. (2019) · Frontiers in Public Health · doi:10.3389/fpubh.2019.00348 · Cited by 60 · cited 1×
“coli (DAEC), which are important in specific regions globally.(37) In SSA, the precise burden associated with diarrheagenic E.”
BackgroundThe Maturing Antibiotic Mantra: “Shorter Is Still Better”
Spellberg, B. (2018) · Journal of Hospital Medicine · doi:10.12788/jhm.2904 · Cited by 56
Tack, B., Phoba, M.-F., Barbé, B., Mbuyi-Kalonji, L., Hardy, L., Puyvelde, S. V., Ingelbeen, B., Falay, D., Dauly, N., van der Sande, M. A. B., et al. (2020) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0008121 · Cited by 56
Kariuki, S., Mbae, C., Van Puyvelde, S., Onsare, R., Kavai, S., Wairimu, C., Ngetich, R., Clemens, J., & Dougan, G. (2020) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0008440 · Cited by 56
Self-citationAruhomukama, D., Najjuka, C. F., Kajumbula, H., Okee, M. S., Mboowa, G., Sserwadda, I., Mayanja, R., Joloba, M. L., & Kateete, D. P. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4510-5 · Cited by 55
Musila, L., Kyany’a, C., Maybank, R., Stam, J., Oundo, V., & Sang, W. (2021) · PLOS ONE · doi:10.1371/journal.pone.0246937 · Cited by 55
Kiyaga, S., Kyanya, C. K., Muraya, A. W., Smith, H. J., Mills, E. G., Kibet, C. K., Mboowa, G., & Musila, L. A. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.835403 · Cited by 55
Perovic, O., Iyaloo, S., Kularatne, R., Lowman, W., Bosman, N., Wadula, J., Seetharam, S., Duse, A., Mbelle, N., Bamford, C., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0145429 · Cited by 54
Seidman, J. C., Johnson, L. B., Levens, J. P., Mkocha, H. A., Muñoz, B. E., Silbergeld, E. K., West, S. K., & Coles, C. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01420 · Cited by 53 · cited 3×
“According to the World Health Organization (WHO) report on surveillance of antimicrobial consumption, in 65 countries, consumption ranged from 4.4 to 64.4 DDD per 1000 population per day.27 In the four SSA countries assessed, consumption ranged from 4.4 DDD in Burundi to 27.29 DDD per 1000 population per day in Tanzan…”
BackgroundInfluentialFluoroquinolone-Resistant Typhoid, South Africa
Keddy, K. H., Smith, A. M., Sooka, A., Ismail, H., & Oliver, S. (2010) · Emerging infectious diseases · doi:10.3201/eid1605.091917 · Cited by 52
Yallew, W. W., Kumie, A., & Yehuala, F. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181145 · Cited by 52 · cited 1×
“pneumoniae are poor hand hygiene among healthcare workers, contaminated medical equipment, and poor waste management practices in hospitals.(123,124) These drivers are associated with inadequate supply of equipment, poor infrastructure relating to infection control, and understaffed healthcare settings, which result i…”
BackgroundLowe, M., Ehlers, M. M., Ismail, F., Peirano, G., Becker, P., Pitout, J. D. D., & Kock, M. M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01280 · Cited by 50
Park, S. E., Pham, D. T., Pak, G. D., Panzner, U., Maria Cruz Espinoza, L., von Kalckreuth, V., Im, J., Mogeni, O. D., Schütt-Gerowitt, H., Crump, J. A., et al. (2021) · BMJ Global Health · doi:10.1136/bmjgh-2021-005659 · Cited by 50 · cited 3×
“Invasive strains of multidrug-resistant NTS circulating in SSA are predominantly S. Typhimurium ST313 and S. Enteritidis ST11, although S. Dublin ST10 has only been associated with resistance in West Africa.96,104 These strains harbor the notorious Tn21 transposon on an incF plasmid (pSLT-BT), which contains a plethor…”
BackgroundKariuki, S., Dyson, Z. A., Mbae, C., Ngetich, R., Kavai, S. M., Wairimu, C., Anyona, S., Gitau, N., Onsare, R. S., Ongandi, B., et al. (2021) · eLife · doi:10.7554/elife.67852 · Cited by 50
Self-citationSalmonella Bacteremia Among Children in Central and Northwest Nigeria, 2008–2015
Obaro, S. K., Hassan-Hanga, F., Olateju, E. K., Umoru, D., Lawson, L., Olanipekun, G., Ibrahim, S., Munir, H., Ihesiolor, G., Maduekwe, A., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ745 · Cited by 48
Vandenberg, O., Nyarukweba, D. Z., Ndeba, P. M., Hendriksen, R. S., Barzilay, E. J., Schirvel, C., Bisimwa, B. B., Collard, J.-M., Aidara Kane, A., & Aarestrup, F. M. (2010) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181cd615a · Cited by 48
Simon, B., & Kazaura, M. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s263517 · Cited by 48
Aldrich, C., Hartman, H. B., Feasey, N., Chattaway, M. A., Dekker, D. M., Al‐Emran, H. M., Larkin, L., McCormick, J., Sarpong, N., Hello, S. L., et al. (2019) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0007485 · Cited by 46
Invasive Salmonella Infections Among Children From Rural Mozambique, 2001–2014
Mandomando, I., Bassat, Q., Sigaúque, B., Massora, S., Quintó, L., Ácacio, S., Nhampossa, T., Vubil, D., Garrine, M., Macete, E., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ712 · Cited by 44
Kariuki, S., Mbae, C., Onsare, R., Kavai, S. M., Wairimu, C., Ngetich, R., Ali, M., Clemens, J., & Dougan, G. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy898 · Cited by 44 · cited 3×
“Enteriditis.(96) A review published in 2017(93) found that since 1966, NTS has been a major cause of bacteremia in 33 out of 54 African countries, accounting for up to 39% of community-acquired bloodstream infections in the region and resulting in an average case fatality rate of 19%.”
BackgroundSelf-citationSalmonella Typhi From Blood Cultures in the Democratic Republic of the Congo: A 10-Year Surveillance
Tack, B., Phoba, M.-F., Puyvelde, S. V., Mbuyi-Kalonji, L., Hardy, L., Barbé, B., van der Sande, M. A. B., Monsieurs, E., Deborggraeve, S., Lunguya, O., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1116 · Cited by 42
Codjoe, F. S., Brown, C. A., Smith, T. J., Miller, K., & Donkor, E. S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222168 · Cited by 40
Amsalu, T., Genet, C., & Adem, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-86743-9 · Cited by 40
Kateete, D. P., Nakanjako, R., Okee, M., Joloba, M. L., & Najjuka, C. F. (2017) · BMC Research Notes · doi:10.1186/s13104-017-2612-y · Cited by 39
Villalón, P., Ortega, M., Sáez-Nieto, J. A., Carrasco, G., Medina-Pascual, M. J., Garrido, N., & Valdezate, S. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00593 · Cited by 39 · cited 1×
“baumannii), is the most clinically relevant.(132,133) Acinetobacter baumannii accounts for the majority (approximately 90%) of clinical infections, followed by A.”
BackgroundOmolajaiye, S. A., Afolabi, K. O., & Iweriebor, B. C. (2020) · BioMed Research International · doi:10.1155/2020/4250165 · Cited by 39
A genomic infection control study for Staphylococcus aureus in two Ghanaian hospitals
Donkor, E. S., Jamrozy, D., Mills, R. O., Dankwah, T., Amoo, P., Egyir, B., Badoe, E., Twasam, J., & Bentley, S. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s167639 · Cited by 37
Sahiledengle, B., Seyoum, F., Abebe, D., Geleta, E. N., Negash, G., Kalu, A., Woldeyohannes, D., Tekalegn, Y., Zenbaba, D., & Edward Quisido, B. J. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-037997 · Cited by 37 · cited 1×
“In SSA, high-risk populations are newborns and patients admitted to intensive care units (ICUs), especially those with underlying comorbidities.(121,122) The main driving factors for resistant K.”
BackgroundKumwenda, P., Adukwu, E. C., Tabe, E. S., Ujor, V. C., Kamudumuli, P. S., Ngwira, M., Wu, T.-S. J., & Chisale, M. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-020-05725-w · Cited by 37
Ayenew, Z., Tigabu, E., Seyoum, E., Ebrahim, S., Assefa, D., & Tsige, E. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250896 · Cited by 36
Bacteremia Among Febrile Patients Attending Selected Healthcare Facilities in Ibadan, Nigeria
Popoola, O., Kehinde, A., Ogunleye, V., Adewusi, O. J., Toy, T., Mogeni, O. D., Aroyewun, E. O., Agbi, S., Adekanmbi, O., Adepoju, A., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz516 · Cited by 35 · cited 1×
“Typhi, while 1% had invasive non-typhoidal Salmonella (iNTS) infections.(72) All of the Salmonella isolates except one showed multidrugresistance”
BackgroundUpdated research agenda for water, sanitation and antimicrobial resistance
Sano, D., Wester, A. L., Schmitt, H., Amarasiri, M., Kirby, A. E., Medlicott, K. O., & Husman, A. M. D. R. (2020) · Journal of Water and Health · doi:10.2166/wh.2020.033 · Cited by 34
Population Structure of Clinical Pseudomonas aeruginosa from West and Central African Countries
Cholley, P., Ka, R., Guyeux, C., Thouverez, M., Guessennd, N., Ghebremedhin, B., Frank, T., Bertrand, X., & Hocquet, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107008 · Cited by 31
Walters, M. S., Routh, J. A., Mikoleit, M. L., Kadivane, S., Ouma, C., Mubiru, D., Ben, M., Amos, M., Ejoku, E., Absalom, R., et al. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0002726 · Cited by 31
Falay, D., Kuijpers, L. M. F., Phoba, M.-F., Boeck, H. D., Lunguya, O., Vakaniaki, E. H., Bertrand, S., Mattheus, W., Ceyssens, P., Vanhoof, R., et al. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1604-1 · Cited by 31
Ayibieke, A., Kobayashi, A., Suzuki, M., Sato, W., Mahazu, S., Prah, I., Mizoguchi, M., Moriya, K., Hayashi, T., Suzuki, T., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.587398 · Cited by 31 · cited 1×
“baumannii is predominantly mediated by carbapenem-hydrolyzing Ambler class D β-lactamases (CHDLs), especially the oxacillinase (OXA) type, and Ambler class B metallo-β-lactamases (MBLs).(145) Studies in SSA have detected CHDL genes, including blaOXA-23-like, blaOXA-24-like, blaOXA-58-like, blaOXA-143-like, and blaOXA-…”
BackgroundBurden of Invasive NontyphoidalSalmonellaDisease in a Rural and Urban Site in Kenya, 2009–2014
Verani, J. R., Toroitich, S., Auko, J., Kiplangat, S., Cosmas, L. O., Audi, A. O., Mogeni, O. D., Aol, G., Oketch, D. C. O., Odiembo, H., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ728 · Cited by 30
Shuping, L. L., Kuonza, L., Musekiwa, A., Iyaloo, S., & Perovic, O. (2017) · PLOS ONE · doi:10.1371/journal.pone.0188216 · Cited by 30 · cited 1×
“The most common risk factors associated with MRSA infection are HIV infection, prior antibiotic use, ICU admission, prior or prolonged hospitalization, indwelling catheters, invasive procedures, open wounds and burns, residency at long-term care facilities, mechanical ventilation, renal failure, and MRSA colonization…”
BackgroundAwol, R. N., Reda, D. Y., & Daka, D. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-020-05726-9 · Cited by 30
Vibrio cholerae O1 lineages driving cholera outbreaks during seventh cholera pandemic in Ghana
Thompson, C. C., Freitas, F. S., Marin, M. A., Fonseca, E. L., Okeke, I. N., & Vicente, A. C. P. (2011) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2011.08.020 · Cited by 29
Laboratory characterisation of Salmonella enterica serotype Typhi isolates from Zimbabwe, 2009–2017
Mashe, T., Gudza-Mugabe, M., Tarupiwa, A., Munemo, E., Mtapuri‐Zinyowera, S., Smouse, S. L., Sooka, A., Stray‐Pedersen, B., Smith, A. M., & Mbanga, J. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4114-0 · Cited by 28
Danso, E. K., Asare, P., Otchere, I. D., Akyeh, L. M., Asante-Poku, A., Aboagye, S. Y., Osei-Wusu, S., Opare, D., Ntoumi, F., Zumla, A., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0236016 · Cited by 28 · cited 1×
“cholerae isolates have become resistant to penicillins, aminoglycosides and sulfonamides, quinolones, tetracycline, macrolides, and phenicols, and more recently several studies have reported strains showing reduced susceptibility to fluoroquinolones and third generation cephalosporins.(54,57,58,60) This resistance has…”
BackgroundOlaniran, O. B., Adeleke, O. E., Donia, A., Shahid, R., & Bokhari, H. (2021) · Current Microbiology · doi:10.1007/s00284-021-02706-3 · Cited by 28
Emergence of oxacillinase-181 carbapenemase-producing diarrheagenic Escherichia coli in Ghana
Prah, I., Ayibieke, A., Mahazu, S., Sassa, C. T., Hayashi, T., Yamaoka, S., Suzuki, T., Iwanaga, S., Ablordey, A., & Saito, R. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1920342 · Cited by 27 · cited 1×
“In addition, it harbored the qnrS1 gene, which confers resistance to fluoroquinolones in an IS26 transposon.(47) An ST410 with the blaNDM-1 gene contained in an IncHI1, as well as Tn125 transposon, and an ISSm-1-like insertion sequence belonging to the novel IS110 family has also been reported, further raising concern…”
BackgroundMultidrug-Resistant Salmonella enterica Serotype Typhi, Gulf of Guinea Region, Africa
Baltazar, M., Ngandjio, A., Holt, K. E., Lepillet, E., Pardos de la Gandara, M., Collard, J.-M., Bercion, R., Nzouankeu, A., Le Hello, S., Dougan, G., et al. (2015) · Emerging Infectious Diseases · doi:10.3201/eid2104.141355 · Cited by 26
(2018) · PubMed · doi:10.4103/njcp.njcp_229_17 · Cited by 26 · cited 1×
“Of concern is its resistance to beta-lactams,(175) especially carbapenems, as they are often used for empiric treatment of last resort.(176) The WHO has listed carbapenem-resistant P.”
BackgroundAyibieke, A., Sato, W., Mahazu, S., Prah, I., Addow-Thompson, J., Ohashi, M., Suzuki, T., Iwanaga, S., Ablordey, A. S., & Saito, R. (2018) · PLoS ONE · doi:10.1371/journal.pone.0209623 · Cited by 26 · cited 1×
“An ST410 with the blaNDM-1 gene contained in an IncHI1, as well as Tn125 transposon, and an ISSm-1-like insertion sequence belonging to the novel IS110 family has also been reported, further raising concerns regarding the effectiveness of carbapenems in treatment.(45) Currently, no licensed vaccine is available for di…”
BackgroundPossible Dissemination of Escherichia coli Sequence Type 410 Closely Related to B4/H24RxC in Ghana
Mahazu, S., Prah, I., Ayibieke, A., Sato, W., Hayashi, T., Suzuki, T., Iwanaga, S., Ablordey, A., & Saito, R. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.770130 · Cited by 26
Ogbolu, D. O., Alli, O. A. T., Oluremi, A. S., Ogunjimi, Y. T., Ojebode, D. I., Dada, V. K., Alaka, O. O., Foster-Nyarko, E., & Webber, M. A. (2020) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2020.1775881 · Cited by 25
Feglo, P. K., & Sewurah, M. (2018) · BMC Research Notes · doi:10.1186/s13104-017-2923-z · Cited by 24 · cited 1×
“cholerae isolates have become resistant to penicillins, aminoglycosides and sulfonamides, quinolones, tetracycline, macrolides, and phenicols, and more recently several studies have reported strains showing reduced susceptibility to fluoroquinolones and third generation cephalosporins.(54,57,58,60) This resistance has…”
BackgroundMsolo, L., Iweriebor, B. C., & Okoh, A. I. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s269219 · Cited by 24
Ouédraogo, A.-S., Compain, F., Sanou, M., Aberkane, S., Bouzinbi, N., Hide, M., Sangaré, L., Ouédraogo-Traoré, R., Jean-Pierre, H., Vendrell, J., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00147-16 · Cited by 23
Iramiot, J. S., Rwego, I. B., Kansiime, C., & Asiimwe, B. (2019) · BMC Public Health · doi:10.1186/s12889-019-7798-6 · Cited by 23
Awuor, S. O., Omwenga, E. O., & Daud, I. I. (2020) · African Journal of Primary Health Care & Family Medicine · doi:10.4102/phcfm.v12i1.2264 · Cited by 23
Rizk, S. S., Elwakil, W. H., & Attia, A. S. (2021) · Antibiotics · doi:10.3390/antibiotics10070764 · Cited by 23
Nyirenda, T. S., Nyirenda, J., Tembo, D. L., Storm, J., Dube, Q., Msefula, C. L., Jambo, K., Mwandumba, H. C., Heyderman, R. S., Gordon, M. A., et al. (2017) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00057-17 · Cited by 22
Webale, M. K., Wanjala, C. L., Guyah, B., Shaviya, N., Munyekenye, G. O., Nyanga, P. L., Marwa, I. N., Njeru, S. K., Wangai, L. N., Webale, S. K., et al. (2020) · Gastroenterology and hepatology from bed to bench. · Cited by 22
Cornick, J., Musicha, P., Peno, C., Seager, E., Tam, P. I., Bilima, S., Bennett, A., Kennedy, N., Feasey, N., Heinz, E., et al. (2021) · Microbial Genomics · doi:10.1099/mgen.0.000703 · Cited by 22
Moon, H. Y., Lee, D. W., Sim, G. H., Kim, H.-J., Hwang, J. Y., Kwon, M., Kang, B.-K., Kim, J. M., & Kang, H. A. (2016) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2016.07.006 · Cited by 21
Adewale, A. K., Pazhani, G. P., Abiodun, I. B., Afolabi, O., Kolawole, O. D., Mukhopadhyay, A. K., & Ramamurthy, T. (2016) · PLOS ONE · doi:10.1371/journal.pone.0159794 · Cited by 21
Amoako, D. G., Bester, L. A., Somboro, A. M., Baijnath, S., Govind, C., & Essack, S. Y. (2016) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.03.019 · Cited by 20 · cited 1×
“This has been attributed to the presence of several genes; aac(6’)-Ie-aph(2”)-Ia, aph(3’)-IIIa, ant(4’)-Ia, apH3, and aacA-aphD, conferring resistance to aminoglycosides; tetK/M genes against tetracycline; dfrG/dfrA genes against trimethoprim; ermA, ermC, or msrA genes against clindamycin; and gyrA and grlA genes agai…”
BackgroundMutai, W. C., Waiyaki, P. G., Kariuki, S., & Muigai, A. W. T. (2019) · BMC Research Notes · doi:10.1186/s13104-019-4468-9 · Cited by 20
Self-citationOdih, E. E., Irek, E. O., Obadare, T. O., Oaikhena, A. O., Afolayan, A. O., Underwood, A. P., Adenekan, A. T., Ogunleye, V. O., Argimón, S., Dalsgaard, A., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.846051 · Cited by 20
Webale, M., Wanjala, C., Guyah, B., Shaviya, N., Munyekenye, G. O., Nyanga, P. L., Marwa, I., Kagoiyo, S., Wangai, L., Webale, S. K., et al. (2020) · Gastroenterology and hepatology from bed to bench · doi:10.22037/ghfbb.v13i3.1910 · Cited by 19
Genomic comparison of serogroups O159 and O170 with other Vibrio cholerae serogroups
Li, Z., Lü, X., Wang, D., Liang, W. L., Zhang, J., Li, J., Xu, J., Pang, B., & Kan, B. (2019) · BMC Genomics · doi:10.1186/s12864-019-5603-7 · Cited by 18
Salmonella enterica serovar Typhi H58 clone has been endemic in Zimbabwe from 2012 to 2019
Mashe, T., Leekitcharoenphon, P., Mtapuri‐Zinyowera, S., Kingsley, R. A., Robertson, V. J., Tarupiwa, A., Kock, M. M., Makombe, E. P., Chaibva, B. V., Manangazira, P., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa519 · Cited by 18 · cited 1×
“1 genotype has been attributed to the presence of translocated regions containing plasmids such as IncHI1 and IncN (subtype PST3),(66,69,73,77,78) and the presence of chromosomal mutations in the quinolone resistance-determining regions (QRDRs) of genes parC, gyrA, gyrB, and gyrS.(73,78) One of the key factors that ha…”
BackgroundSmith, A. M., Njanpop-Lafourcade, B.-M., Mengel, M. A., Gessner, B. D., Sauvageot, D., Bidjada, B., Miwanda, B. N., Saliou, D. M., N’Douba, A. K., Langa, J. P., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0142989 · Cited by 16 · cited 1×
“cholerae isolates have become resistant to penicillins, aminoglycosides and sulfonamides, quinolones, tetracycline, macrolides, and phenicols, and more recently several studies have reported strains showing reduced susceptibility to fluoroquinolones and third generation cephalosporins.(54,57,58,60) This resistance has…”
BackgroundInvasive atypical non-typhoidal Salmonella serovars in The Gambia
Kanteh, A., Sesay, A. K., Alikhan, N.-F., Ikumapayi, U. N., Salaudeen, R. A., Manneh, J., Olatunji, Y., Page, A. J., & Mackenzie, G. A. (2021) · Microbial Genomics · doi:10.1099/mgen.0.000677 · Cited by 16
Olu-Taiwo, M., Opintan, J. A., Codjoe, F. S., & Forson, A. O. (2020) · BioMed Research International · doi:10.1155/2020/3852419 · Cited by 15
Verdú-Expósito, C., Romanyk, J., Cuadros-González, J., TesfaMariam, A., Copa-Patiño, J. L., Pérez-Serrano, J., & Soliveri, J. (2020) · PLOS ONE · doi:10.1371/journal.pone.0230031 · Cited by 15
Kaluba, C. K., Samutela, M. T., Kapesa, C., Muma, J. B., Hang'ombe, B. M., Hachaambwa, L., Mukomena, P., & Yamba, K. (2021) · Scientific African · doi:10.1016/j.sciaf.2021.e00908 · Cited by 15
Epidemiology of Staphylococcus aureus Infections in Kenya: Current State, Gaps and Opportunities
Nyasinga, J., Omuse, G., John, N., Nyerere, A., Abdulgader, S., Newton, M., Whitelaw, A., & Revathi, G. (2020) · Open Journal of Medical Microbiology · doi:10.4236/ojmm.2020.104018 · Cited by 14
Identification of Atypical El TorV. cholerae O1 Ogawa Hosting SXT Element in Senegal, Africa
Sambe-Ba, B., Diallo, M. H., Abdoulaye, S., Wane, A. A., de Magny, G. C., Boye, C. S.-B., Sow, A. I., & Gassama‐Sow, A. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00748 · Cited by 12
Steinhaus, N., Al-talib, M., Ive, P., Boyles, T., Bamford, C., Davies, M.-A., Mendelson, M., & Wasserman, S. (2018) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2018.06.004 · Cited by 12 · cited 1×
“The most common risk factors associated with MRSA infection are HIV infection, prior antibiotic use, ICU admission, prior or prolonged hospitalization, indwelling catheters, invasive procedures, open wounds and burns, residency at long-term care facilities, mechanical ventilation, renal failure, and MRSA colonization…”
BackgroundThe UK Fleming Fund: Developing AMR surveillance capacity in low- and middle-income countries
Gordon, N., Aggarwal, V., Amos, B., Buhler, C., Huszar, A., McKenzie, J., Mitchell, J., Moyen, N., Mubangizi, P., & Leslie, T. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.09.137 · Cited by 12
Ackers-Johnson, G., Kibombo, D., Kusiima, B., Nsubuga, M. L., Kigozi, E., Kajumbula, H. M., Kateete, D. P., Walwema, R., Ackers, H. L., Goodhead, I. B., et al. (2021) · Microbiology · doi:10.1099/mic.0.001000 · Cited by 12
Mabika, R. M., Liabagui, S. L. O., Moundounga, H. K., Mounioko, F., Souza, A., & Yala, J. F. (2021) · Open Journal of Medical Microbiology · doi:10.4236/ojmm.2021.113013 · Cited by 12
D, A., J, B., & S, G. (2017) · African Journal of Infectious Diseases · doi:10.21010/ajid.v11i2.9 · Cited by 11
Jeon, H. J., Im, J., Haselbeck, A., Holm, M., Rakotozandrindrainy, R., Soura, A., Panzner, U., Mogeni, O. D., Seo, H. J., Lunguya, O., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz629 · Cited by 10
Vubil, D. C., Garrine, M., Ruffing, U., Acácio, S., Sigaúque, B., Alonso, P. L., von Müller, L., Herrmann, M., & Mandomando, I. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00730 · Cited by 9
Somda, N. S., Bonkoungou, O. J. I., Zongo, C., Kpoda, D. S., Tapsoba, F., Bassolé, I. H. N., Traoré, Y., & Savadogo, A. (2017) · African Journal of Clinical and Experimental Microbiology · doi:10.4314/ajcem.v18i4.1 · Cited by 9
Kariuki, S., & Owusu‐Dabo, E. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa315 · Cited by 9 · cited 1×
“Other significant host factors are anemia and sickle cell.(92,93) In urban areas where iNTS is endemic, malnutrition plays a key role in adult infection, especially where exposure to malaria is minimal.”
BackgroundSelf-citationPseudomonas aeruginosa bloodstream infection at a tertiary referral hospital for children
Dame, J. A., Beylis, N., Nuttall, J. J. C., & Eley, B. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05437-1 · Cited by 9 · cited 1×
“Pseudomonas aeruginosa Pseudomonas aeruginosa is a Gram-negative bacterium commonly found in water and soil.(173) It is an opportunistic pathogen commonly associated with hospital-acquired infections, particularly bloodstream infections, urinary tract infections, and pneumonia, resulting in considerable morbidity and…”
BackgroundMolecular Characterization of Extended Spectrum β-Lactamase Genes in Clinical E. coli Isolates
Igwe, J. C., Onaolapo, J. A., Kachallah, M., Nworie, A., Oladipo, H. O., Ojiego, B. O., Enose, O. D., Adeboye, S. E., Durowaiye, M. T., Akpa, A. U., et al. (2014) · Journal of Biomedical Science and Engineering · doi:10.4236/jbise.2014.75030 · Cited by 8
Ettu, A. O., Oladapo, B. A., & Oduyebo, O. O. (2021) · African Journal of Clinical and Experimental Microbiology · doi:10.4314/ajcem.v22i4.10 · Cited by 8
Leaving no one behind: the need for a truly global response to antimicrobial resistance
Goldberg, J., Clezy, K., Jasovský, D., & Uyen-Cateriano, A. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00303-7 · Cited by 8 · cited 17×
“Some of the challenges that hinder the implementation of NAPs are: 1) a lack of political commitment, 2) inadequate funding, 3) poor coordination and collaboration between the different sectors, 4) inadequate surveillance Infection and Drug Resistance 2022:15 https://doi.org/10.2147/IDR.S342753 DovePress 3601 Powered…”
BackgroundInfluentialGarbati, M. A., Baba, A., Mursal, A., & Gadzama, G. (2019) · Sub-Saharan African Journal of Medicine · doi:10.4103/ssajm.ssajm_12_19 · Cited by 7
Founou, R. C., Founou, L. L., Allam, M., Ismail, A., & Essack, S. Y. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.05.012 · Cited by 7 · cited 1×
“aeruginosa has an intrinsic resistance to several antibiotics, it can develop resistance through the acquisition of resistance genes.(182,183) Various carbapenemase-encoding genes have been observed: blaIMP, blaSPM, blaVIM, blaNDM, blaOXA-23, blaOXA-48 blaSIM, blaAIM, blaBIC-1, blaNMC-A, and blaOXA-58.”
BackgroundNegeri, A. A., Eyasu, T. S., Rajiha, A. I., & Mamo, H. (2019) · African Journal of Microbiology Research · doi:10.5897/ajmr2018.9030 · Cited by 3
Research works printed but not linked: 6
- 2014, Estimating the Economic Costs of Antimicrobial Resistance
- Webale, 2020, Gastroenterol Hepatol Bed Bench, 13, 238
- Kanteh, 2021, Microb Genom, 7, 000677
- Cornick, 2021, Microb Genom, 7, 000703
- 2022, StatPearls
- Murray, 2022, Lancet, 399, 629, 10.1016/S0140-6736(21)02724-0 · DOI · Paper page
Cited by
Naghavi, M., Vollset, S. E., Ikuta, K. S., Swetschinski, L. R., Gray, A. P., Wool, E. E., Robles Aguilar, G., Mestrovic, T., Smith, G., Han, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01867-1 · Cited by 3,791
“60,72,73 In some countries, available data are fragmented, undersampled, or not representative of the broader population.”
Sartorius, B., Gray, A. P., Davis Weaver, N., Robles Aguilar, G., Swetschinski, L. R., Ikuta, K. S., Mestrovic, T., Chung, E., Wool, E. E., Han, C., et al. (2024) · The Lancet Global Health · doi:10.1016/s2214-109x(23)00539-9 · Cited by 354
“35,36 Available data in some countries are often fragmented, undersampled, or not necessarily representative of the general underlying population.”
BackgroundGlobal burden of antimicrobial resistance and forecasts to 2050
Kariuki, S. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01885-3 · Cited by 190
Self-citationGlobal Strategies to Combat Antimicrobial Resistance: A One Health Perspective
Mudenda, S., Chabalenge, B., Daka, V., Mfune, R. L., Salachi, K. I., Mohamed, S., Mufwambi, W., Kasanga, M., & Matafwali, S. K. (2023) · Pharmacology & Pharmacy · doi:10.4236/pp.2023.148020 · Cited by 144
Sono, T. M., Yeika, E., Cook, A., Kalungia, A., Opanga, S. A., Acolatse, J. E. E., Sefah, I. A., Jelić, A. G., Campbell, S., Lorenzetti, G., et al. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2259106 · Cited by 95
“For instance in Ghana, there are still concerns due to the lack of available resources and commitment to fully progress their NAP [27], which is similar to other African countries with limited resources and technologies allocated to AMR mitigation [28].”
Background
Metadata
- Authors
- Kariuki, S., Kering, K., Wairimu, C., Onsare, R., & Mbae, C.
- Affiliations
- Kenya Medical Research Institute (KE)
- Corresponding author
- Kariuki, Samuel
- Kering, Kelvin
- Wairimu, Celestine
- Mbae, Cecilia
- Venue
- Infection and Drug Resistance
- Publisher
- Informa UK Limited
- Published
- 2022-07
- Volume
- Volume 15
- Pages
- 3589-3609
- ISSN
- 1178-6973 (ISSN-L)
- PMC
- PMC9273632
- OpenAlex
- W4284678172
- Cited by
- 245
- References
- 189
- Citations by year
- 2026: 72 · 2025: 92 · 2024: 53 · 2023: 27 · 2022: 1
- FWCI
- 5.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Infection and Drug Resistance (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc-sa)
- Funders
- Wellcome Trust (215675/Z/19/Z)
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R01AI099525)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Agricultural and Biological Sciences › Food Science › Salmonella and Campylobacter epidemiology
- Keywords
- antimicrobial resistance, antimicrobial resistance surveillance, sub-Saharan Africa, national action plans, One Health, antimicrobial stewardship, infection control, water, sanitation and hygiene, antimicrobial use regulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.